Avita Medical(RCEL) Stock Options Chain | Quotes & News
This article provides details on Avita Medical's (RCEL) stock options chain, offering quotes and news related to the company's financial instruments. It serves as a resource for investors interested in RCEL's options performance and market activities.
Avita Medical (RCEL) Upgraded to Buy: Here's Why
Avita Medical (RCEL) has been upgraded to a Zacks Rank #2 (Buy) due to an upward trend in its earnings estimates. The Zacks rating system highlights the strong correlation between revisions in earnings estimates and near-term stock price movements, making this upgrade a positive indicator for Avita Medical's stock. The company's earnings estimates for fiscal year ending December 2026 have increased by 11.4% over the past three months, positioning it in the top 20% of Zacks-covered stocks.
Avita Medical Downgraded to Hold From Speculative Buy by Morgans
Morgans has downgraded Avita Medical (ASX:AVH) from a "Speculative Buy" to a "Hold" rating. This change reflects a revised outlook from the analyst following a recent assessment of the company. Investors should consider this updated rating in their evaluation of Avita Medical's stock.
Price to sales forward of AVITA Medical Inc Shs Chess Depository Interests repr 0.2 shs – ASX:AVH
This page from TradingView displays the "Price to sales forward" financial metric for AVITA Medical Inc Shs Chess Depository Interests, traded on the Australian Securities Exchange under the ticker ASX:AVH. The article provides a high-level overview of the company's financial data. It also mentions that the trading market was closed with no trades at the time of viewing.
AVITA Medical, Inc.(NasdaqCM: RCEL) dropped from Russell 3000 Index
AVITA Medical, Inc. (NasdaqCM: RCEL) has been removed from the Russell 3000 Index, along with several other Russell indices including the Russell Small Cap Comp Growth Benchmark, Russell 2500 Growth Benchmark, and Russell 2000 Dynamic Index. This news was published on June 29, 2026, and is significant for investors tracking the company's inclusion in major market indices. The company specializes in acute wound care with products like RECELL, PermeaDerm, and Cohealyx.
Enterprise value to EBITDA forward of Avita Medical, Inc. – NASDAQ:RCEL
This article focuses on the enterprise value to EBITDA forward for Avita Medical, Inc. (NASDAQ: RCEL). It seems to be a financial data point from TradingView, indicating a specific valuation metric for the company. The content primarily presents navigation and various data source acknowledgments rather than detailed financial analysis.
Bronstein, Gewirtz & Grossman, LLC Is Investigating AVITA Medical
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of AVITA Medical, Inc. (NASDAQ:RCEL) after the company's stock fell 25.8% following the announcement of its CEO's immediate departure. Investors who purchased AVITA securities are encouraged to contact the firm to assist with the investigation. The firm represents investors in class actions on a contingency fee basis.
Price to book forward of AVITA Medical Inc – LS:A2P733
This article provides financial information for AVITA Medical Inc (LS:A2P733) on TradingView, specifically focusing on its forward price-to-book ratio. The content is brief, indicating that the market was closed at the time of viewing and no trades were recorded for the stock.
Price to sales forward of Avita Medical, Inc. – NASDAQ:RCEL
This article provides financial information for Avita Medical, Inc. (NASDAQ: RCEL), specifically focusing on its forward price-to-sales ratio. It presents a simple table with the period, value, change, and percentage change for this metric, noting that the data is sourced from FactSet and ICE Data Services.
BTIG Maintains Avita Medical(RCEL.US) With Hold Rating
BTIG has reiterated its Hold rating for Avita Medical (RCEL.US). This update indicates the firm's ongoing stance on the company's stock.
AVITA Medical Highlights First U.K. Clinical Experience with RECELL GO at British Burn Association Annual Meeting
AVITA Medical presented new clinical data at the British Burn Association Annual Meeting, showcasing the first U.K. use of its RECELL GO system. A case series of 17 burn and reconstructive surgery patients at Stoke Mandeville Hospital demonstrated successful outcomes and improved operating room workflow with RECELL GO. The system's ability to standardize cell preparation and its clinical benefits are expected to expand access to advanced autologous cell therapies globally.
AVITA Medical’s burn treatment used in 17 U.K. patients
AVITA Medical (NASDAQ: RCEL) announced the successful use of its RECELL GO system in 17 burn and reconstructive patients in the UK, with all patients discharged without complications and noted workflow benefits for the surgical teams. The findings were presented at the 2026 British Burn Association Annual Meeting and supported by a systematic review of over 8,000 patients, confirming RECELL's safety and effectiveness. RECELL GO is CE-marked in Europe/UK and recently authorized in Australia and New Zealand, indicating its expanding international presence.
AVITA Medical Highlights First U.K. Clinical Experience with RECELL GO at British Burn Association Annual Meeting
AVITA Medical announced new clinical data from the first documented use of RECELL GO in the United Kingdom, presented at the 2026 British Burn Association Annual Meeting. The case series, involving 17 burn and reconstructive surgery patients at Stoke Mandeville Hospital, demonstrated successful use of RECELL GO, standardization of preparation, and improved operating room workflow. This highlights the global adoption of RECELL GO for advanced autologous cell therapies.
AVITA Medical Highlights First U.K. Clinical Experience with RECELL GO at British Burn Association Annual Meeting
AVITA Medical announced the presentation of new clinical data at the 2026 British Burn Association Annual Meeting, highlighting the first documented use of RECELL GO in the United Kingdom. A case series from Stoke Mandeville Hospital demonstrated successful outcomes in 17 burn and reconstructive surgery patients, noting improved workflow and standardized cell preparation. The findings support RECELL GO's role in advancing autologous cell therapy and its expanding global adoption.
AVITA Medical Inc (RCEL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a revenue breakdown for AVITA Medical Inc (RCEL), detailing its regional revenue contributions. As of the latest update, the data primarily shows revenue by region, with the United States accounting for the vast majority. The article indicates that business segment data has not yet been disclosed by the company.
AVITA Medical Inc (RCEL) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides historical dividend and stock split information for AVITA Medical Inc (RCEL). It indicates that AVITA Medical Inc has not distributed any dividends over the past five years and shows no data for stock splits. The page primarily serves as a financial data portal for the company.
AVITA Medical Inc (RCEL) Financial Health: Profitability & Balance Sheet Analysis
AVITA Medical Inc (RCEL) has a current financial score of 7.84, placing it 77th out of 388 in the Biotechnology & Medical Research industry, indicating weak financial status but high operating efficiency. The company reported a quarterly revenue of $19.25M, a 3.98% year-over-year increase, and net profit grew by 23.44% year-over-year. However, several key financial metrics like cash and cash equivalents, total assets, total liabilities, free cash flow, operating profit, and income after tax have not been fully disclosed yet.
AVITA Medical Inc (RCEL) Earnings Forecast: Future EPS & Revenue Growth Estimates
AVITA Medical Inc (RCEL) has an earnings forecast score of 8.00, ranking 163rd in its industry. Analysts have set an average price target of $5.50, with a consensus "Buy" rating based on 5 analysts. The company's recent EPS was -$0.38 against an expectation of -$0.35, and the next quarter's EPS is projected to be -$0.31, with expected revenue of $19.93 million.
AVITA Medical Inc (RCEL) Risk Assessment: Volatility, Financial Risk & Investment Risk
AVITA Medical Inc (RCEL) has a risk assessment score of 2.77, ranking it 191 out of 388 in the Biotechnology & Medical Research industry. The company's beta value of 1.88 indicates higher volatility relative to the S&P 500. The risk assessment also details various financial metrics including volatility, maximum drawdown, and Sharpe ratio over different periods.
AVITA Medical (RCEL) CFO receives 2,000-share equity grant in Form 4
AVITA Medical's CFO, David D. O'Toole, was granted 2,000 shares of common stock at a reference value of $3.97 per share. This compensation-related award increased his directly held stake to 152,927 shares, which includes unvested Restricted Stock Units (RSUs). The transaction was reported via a Form 4 filing and is characterized as a grant rather than an open-market purchase.
Avita Medical director Woody Fralin buys $20,800 in common stock
AVITA Medical director Woody Fralin recently purchased 5,200 shares of the company's common stock for $20,800. This transaction increases his direct holdings to 107,961 shares, including unvested Restricted Stock Units. The purchase occurs as AVITA Medical's stock, despite a recent 19% year-to-date increase, is down 32% over the last year and is considered undervalued according to InvestingPro analysis, which also highlights its significant volatility.
AVITA Medical (RCEL) director adds 5,200 shares in open-market buy
AVITA Medical, Inc. director Woody Joseph Fralin purchased 5,200 shares of the company's common stock at $4.00 per share on June 9, 2026, increasing his direct holdings to 107,961 shares, which include unvested Restricted Stock Units (RSUs). This open-market transaction signals insider confidence in the company. The Form 4 filing details the purchase, its impact on his total ownership, and clarifies that the shares are directly held.
Avita Medical director Woody Fralin buys $41,900 in stock
AVITA Medical director Woody Joseph Fralin purchased 10,000 shares of the company's common stock for a total of $41,900 on June 9, 2026. This insider transaction increases his direct ownership to 102,761 shares. The purchase occurred as the stock is considered undervalued by InvestingPro, despite a recent earnings miss but a revenue beat for Q1 2026.
Insider Buying: Joseph Woody Acquires 10,000 Shares of AVITA Med
Joseph Woody, a Director at AVITA Medical Inc (RCEL), purchased 10,000 shares of the company on June 9, 2026, increasing his total holdings to 102,761 shares. This transaction is part of a trend of insider buying at AVITA Medical, with 11 insider buys and no sells over the past year. Despite the insider confidence, the stock's GF Value suggests it might be a "Possible Value Trap," trading at $4.19 against an estimated intrinsic value of $10.73.
Director Woody Fralin buys 10,000 AVITA Medical (RCEL) shares
AVITA Medical, Inc. director Woody Joseph Fralin reported purchasing 10,000 shares of common stock in open-market transactions, priced at $4.18 and $4.20 per share. The total value of these purchases was $41,900. These transactions were disclosed in a Form 4 SEC filing, indicating a positive sentiment from the insider.
AVITA Medical, Inc. Issues Warrant Certificate to Perceptive Credit Holdings V, LP – Details, Terms, and Signatures
AVITA Medical, Inc. (RCEL) has issued a warrant certificate to Perceptive Credit Holdings V, LP, allowing them to purchase up to 650,000 shares of common stock. This agreement, signed by Avita Medical CFO David O’Toole and Perceptive's Sandeep Dixit and Sam Chawla, includes anti-dilution protections, registration rights, and a beneficial ownership limitation for Perceptive. While the deal may signal investor confidence, it also presents potential dilution and market overhang risks for existing shareholders.
AVITA Medical Issues Warrant to Perceptive Tied to $60 Million Credit Facility
AVITA Medical issued a warrant to Perceptive Credit Holdings V following stockholder approval, enabling the purchase of up to 500,000 shares at an exercise price of $3.4019. An additional 150,000 shares will vest if AVITA draws an extra $10 million from its $60 million credit facility. This action, issued on June 5, 2026, supports the company's financing and liquidity.
AVITA Medical (RCEL) registers 650,000 shares tied to Perceptive $3.40 warrant
AVITA Medical (RCEL) has registered 650,000 shares of common stock stemming from a warrant issued to Perceptive Credit Holdings V, LP. Of these, 500,000 shares are currently exercisable, while the remaining 150,000 shares will vest upon the company closing an Additional Commitment Amount. The warrant's exercise price is $3.4019 per share, potentially generating up to $2.2 million for AVITA Medical if fully exercised for cash.
[8-K] AVITA Medical, Inc. Reports Material Event
AVITA Medical, Inc. has reported a material event via an 8-K filing concerning the issuance of a warrant related to its senior secured credit facility of up to $60 million with Perceptive Credit Holdings V, LP. The warrant allows Perceptive to purchase up to 500,000 shares of common stock at $3.4019 per share, with an additional 150,000 shares issuable if an extra $10 million commitment is drawn. Stockholders approved the warrant issuance at the 2026 Annual Meeting, and the shares will be registered under an existing Form S-3.
Insider Buying: Joseph Woody Acquires 10,000 Shares of AVITA Med
Joseph Woody, a Director at AVITA Medical Inc (RCEL), recently purchased 10,000 shares of the company, increasing his total holdings to 92,761 shares. This transaction is part of a trend of insider confidence, with 10 insider buys and no sells over the past year. Despite this, the stock trades at $4.09, while its GF Value is estimated at $10.72, suggesting it might be a "Possible Value Trap."
AVITA Medical (RCEL) director makes 10,000-share open-market stock purchase
AVITA Medical, Inc. director Woody Joseph Fralin reported purchasing 10,000 shares of the company's Common Stock through two open-market transactions on June 3, 2026, at prices of $4.0899 and $4.0999 per share. These purchases increased his direct holdings to 92,761 shares, which include unvested restricted stock units (RSUs). The insider trading activity, disclosed in a Form 4 filing, indicates a positive sentiment from the director towards the company.
AVITA Medical (RCEL) director receives RSU and stock option awards
AVITA Medical director Robert McNamara was granted 22,214 restricted stock units (RSUs) and 16,133 stock options. The RSUs vest 12 months after the January 20, 2026 grant date, while the stock options have an exercise price of $3.77 per share and become exercisable from January 20, 2027. Following these awards, McNamara directly owns 108,985 shares of common stock, including unvested RSUs.
AVITA Medical (NASDAQ: RCEL) grants RSUs and stock options to director
AVITA Medical, Inc. (NASDAQ: RCEL) granted equity awards to director Woody Joseph Fralin, consisting of restricted stock units (RSUs) and stock options in January 2026. These compensation-related grants, approved by stockholders in June 2026, increase his direct common stock holdings to 82,761 shares and vest over time. The grants aim to provide long-term, stock-based compensation.
Director at AVITA Medical (NASDAQ: RCEL) granted RSUs and options
AVITA Medical director Jan Stern Reed received equity awards including 22,214 restricted stock units (RSUs) and 16,133 stock options. The RSUs vest 12 months after the January 20, 2026 grant date, and the stock options have an exercise price of $3.77 and expire on January 20, 2036. Following these awards, Reed directly holds 73,225 shares of common stock, including unvested RSUs, all of which were approved by stockholders on June 3, 2026.
Avita Medical, Inc. Ratifies Appointment of Grant Thornton LLP as Independent Registered Public Accounting Firm
Avita Medical, Inc. announced that at its 2026 Annual Meeting of Stockholders on June 3, 2026, the company ratified the selection of Grant Thornton LLP as its independent registered public accounting firm for the year ending December 31, 2026. This decision confirms the accounting firm's role for the upcoming fiscal year.
AVITA MEDICAL INC-2026 ASM BOARD CHAIR SCRIPT
This document is labelled as the 2026 Annual Shareholder Meeting Board Chair Script for AVITA Medical Inc. No further content is provided beyond the title.
AVITA Medical (NASDAQ: RCEL) investors approve director pay, warrants and extra equity capacity
AVITA Medical (RCEL) stockholders approved all proposals at their 2026 annual meeting, including the election of seven directors, ratification of Grant Thornton LLP as auditor, and an increase in the non-executive director cash fee pool to US$900,000 annually. Investors also backed equity award programs for directors, the issuance of warrants to Perceptive Credit Holdings V, LP covering up to 650,000 shares, and authorized additional equity issuance capacity under ASX Listing Rule 7.1A. Additionally, an advisory vote to approve named executive officer compensation passed, with a preference for annual say-on-pay votes.
Director Woody Fralin buys 20,000 AVITA Medical (RCEL) shares
AVITA Medical, Inc. director Woody Joseph Fralin purchased 20,000 shares of Common Stock in open-market transactions on June 1 and 2, with prices ranging from $4.18 to $4.34 per share. This acquisition increases his direct holdings to 20,000 shares, reflecting a positive sentiment from an insider. The total value of these purchases was approximately $84,937.
Intention to Cease Coverage of IDP Education, Polynovo, Avita, and Clinuvel
Morningstar announced its intention to cease coverage of IDP Education, Polynovo, Avita, and Clinuvel. The company plans to discontinue its investment analysis for these firms on or around June 30, 2026. This announcement highlights upcoming changes in their stock research offerings.
AVITA Medical (RCEL) CFO acquires 5,000 shares through ESPP plan
AVITA Medical, Inc.'s CFO, David D. O'Toole, acquired 5,000 common shares through the company's Employee Share Purchase Plan (ESPP) at a price of $3.0515 per share. This transaction, which was exempt under SEC Rules 16b-3(d) and 16b-3(c), increased his direct holdings to 150,927 shares, including unvested RSUs. The shares were purchased at an 85% discount relative to the closing price on December 1, 2025, for the ESPP period from December 1, 2025, to May 31, 2026.
AVITA Medical (RCEL) CEO adds 5,000 shares through ESPP purchase
AVITA Medical's President and CEO, Vance Cary Guy, acquired 5,000 shares of common stock through the company's Employee Share Purchase Plan (ESPP) at $3.0515 per share. This purchase, made at 85% of the closing price on December 1, 2025, for the ESPP period ending May 31, 2026, increases his direct holdings to 40,771 shares. The transaction is categorized as a compensation-related grant, exempt under SEC Rules 16b-3(d) and 16b-3(c), rather than an open-market trade.
Intention to Cease Coverage of Avita Medical
Morningstar has announced its intention to cease coverage of Avita Medical (AVH: XASX). The company previously anticipated Avita's RECELL product would be successful in challenging the standard of care for larger burns due to its clinical performance, ease of use, and relative price point. RECELL creates "Spray-on Skin" that heals burn sites effectively without creating large donor site wounds.
AVITA Medical (RCEL) CFO adds 2,000 shares in open-market buy
AVITA Medical (RCEL) CFO David D. O'Toole purchased 2,000 shares of common stock in an open-market transaction at $4.26 per share, totaling $8,520. Following this acquisition, O'Toole directly holds 145,927 shares, which include unvested restricted stock units. This insider buy signals confidence in the company, with the transaction detailed in a Form 4 SEC filing dated May 20, 2026.
AVITA Medical to Host Investor Webinar Briefing
AVITA Medical (NASDAQ: RCEL, ASX: AVH) will host an investor webinar briefing on May 20, 2026, featuring its CEO and CFO, to discuss financial and business results from its recent first-quarter 2026 earnings. Additionally, the company is inviting investors to an armchair discussion in Melbourne, Australia, with CEO Cary Vance and veteran healthcare investor Michael Woods, to provide an overview of their commercial progress and 2026 execution priorities. The company specializes in acute wound care solutions, with its key product RECELL, approved by the FDA for thermal burn and trauma wounds.
AVITA Medical (RCEL) CFO adds 2,000 shares in open-market purchase
AVITA Medical, Inc.'s CFO, David D. O'Toole, purchased 2,000 shares of common stock at $4.24 per share through an open-market transaction. This purchase increases his direct holdings to 143,927 shares, which includes unvested restricted stock units. The transaction was filed on Form 4 and indicates a net buy of 2,000 shares valued at $8,480.
Two AVITA Medical investor Q&As with CEO Cary Vance on May 20–21
AVITA Medical (NASDAQ: RCEL) will host two investor Q&A events featuring CEO Cary Vance in May 2026. The first is a webinar on May 20, 2026, at 4:00 p.m. PT (May 21, 2026, at 9:00 a.m. AEST), reviewing Q1 2026 earnings. The second is an in-person armchair discussion in Melbourne on May 21, 2026, at 4:00 p.m. AEST, focusing on the company's acute wound care platform, commercial progress, and 2026 priorities.
AVITA Medical, Inc. (NASDAQ:RCEL) Q1 2026 Earnings Call Transcript
AVITA Medical, Inc. reported its Q1 2026 earnings, with revenues of approximately $19.3 million, up 4% year-over-year and 10% sequentially, meeting EPS expectations of $-0.35. The company leadership emphasized stabilization and improved operational efficiency, driven by normalization of RECELL reimbursement and early traction for Cohealyx. AVITA Medical reaffirmed its full-year 2026 net revenue guidance of $80 million to $85 million, expecting continued sequential growth.
AVITA Medical Q1 2026 earnings preview
This article provides an earnings preview for AVITA Medical's Q1 2026 results. As the content is empty, no specific details regarding financial expectations or previous performance can be included in this summary.
Avita Medical Raised to Buy From Hold by Lake Street
Lake Street has upgraded Avita Medical's rating from Hold to Buy. This change in rating indicates a more positive outlook from the analyst firm regarding the company's stock.
Avita Medical, Inc. Stock 12‑Month Price Target Raised to $6.99, Implies 60% Upside
Avita Medical, Inc.'s average 12-month price target has been increased to $6.99 by analysts, up from $6.67, with forecasts ranging from $4.24 to $10.84 per share. This updated target suggests a potential upside of approximately 60% based on the May 14 closing price. The consensus rating for RCEL remains "Buy" among the 8 covering analysts.
